5 Insightful Analyst Questions From Royalty Pharma's Q4 Earnings Call

Royalty Pharma’s fourth quarter results did not meet Wall Street’s revenue or earnings expectations, with management attributing the performance to a combination of gradual product transitions in key royalty streams and a limited contribution from recent acquisitions. CEO Pablo Legorreta pointed to the diversification and resilience of the portfolio as a mitigating factor, emphasizing that “conversion of CF patients to new therapies has been steady but gradual.” Management also noted that increased capital deployment in late 2025 was balanced by a disciplined approach to share repurchases, reflecting a flexible capital allocation framework.

Is now the time to buy RPRX? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Royalty Pharma’s Q4 Earnings Call

• Geoffrey Meacham (Citi) asked about the sustainability of recent capital returns and whether more funds should be allocated to royalty transactions; CFO Terrance Coyne explained that the capital allocation mix is flexible and currently favors new royalty investments as the opportunity set grows.
• Michael Nedelcovych (TD Cowen) questioned the pace of cystic fibrosis patient conversion to Vertex’s new therapy; Coyne responded that conversion has been gradual and consistent with expectations, and the franchise remains a key long-term contributor.
• Terence Flynn (Morgan Stanley) inquired about the future mix of synthetic versus traditional royalties; EVP Marshall Urist expressed confidence in continued growth of the synthetic royalty market, supported by increasing demand from biopharma companies.
• Asad Haider (Goldman Sachs) sought clarity on which pipeline assets are most underappreciated by Wall Street; Urist highlighted the aggregate royalty potential—over $2 billion in peak royalties—and singled out late-stage cardiovascular and CNS assets as key value drivers.
• Jason Gerberry (Bank of America) probed the differences in deal structuring and diligence for Chinese transactions; CEO Pablo Legorreta stated that the process remains consistent and that a local presence in China will enhance deal sourcing and efficiency.

Catalysts in Upcoming Quarters

In the quarters ahead, we are closely monitoring (1) clinical trial readouts for several high-potential pipeline assets, particularly in oncology and cardiovascular disease; (2) the pace and mix of new synthetic royalty transactions as biopharma funding needs evolve; and (3) execution of cost reductions following the internalization of the management platform. Progress on expanding the company’s presence in China and navigating upcoming loss of exclusivity events will also be critical to watch.

Royalty Pharma currently trades at $45.30, up from $44.21 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.